vs
QWEST CORP（CTBB）与通用电气医疗（OPCH）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是QWEST CORP的1.3倍（$1.4B vs $1.1B），通用电气医疗净利率更高（3.6% vs -187.5%，领先191.1%），通用电气医疗同比增速更快（12.2% vs -15.0%），QWEST CORP自由现金流更多（$160.0M vs $130.2M），过去两年通用电气医疗的营收复合增速更高（13.0% vs -8.6%）
奎斯特公司（以CenturyLink QC名义运营）是一家隶属于 lumen Technologies 的地区性贝尔运营公司。其前身为1911年成立的山地电话电报公司，先后更名为山地贝尔、美国西部通讯，2000年改为现名，业务整合了原Malheur Bell、西北贝尔、太平洋西北贝尔的运营资源。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
CTBB vs OPCH — 直观对比
营收规模更大
OPCH
是对方的1.3倍
$1.1B
营收增速更快
OPCH
高出27.3%
-15.0%
净利率更高
OPCH
高出191.1%
-187.5%
自由现金流更多
CTBB
多$29.8M
$130.2M
两年增速更快
OPCH
近两年复合增速
-8.6%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.4B |
| 净利润 | $-2.1B | $51.8M |
| 毛利率 | 67.9% | 19.0% |
| 营业利润率 | -183.2% | 5.9% |
| 净利率 | -187.5% | 3.6% |
| 营收同比 | -15.0% | 12.2% |
| 净利润同比 | -627.9% | -3.8% |
| 每股收益（稀释后） | — | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTBBOPCH
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $1.3B | $1.2B | ||
| Q1 24 | $1.3B | $1.1B |
净利润CTBBOPCH
| Q4 25 | $-2.1B | — | ||
| Q3 25 | $176.0M | $51.8M | ||
| Q2 25 | $277.0M | $50.5M | ||
| Q1 25 | $284.0M | $46.7M | ||
| Q4 24 | $391.0M | $60.1M | ||
| Q3 24 | $365.0M | $53.9M | ||
| Q2 24 | $378.0M | $53.0M | ||
| Q1 24 | $353.0M | $44.8M |
毛利率CTBBOPCH
| Q4 25 | 67.9% | — | ||
| Q3 25 | 65.3% | 19.0% | ||
| Q2 25 | 68.2% | 19.0% | ||
| Q1 25 | 69.3% | 19.7% | ||
| Q4 24 | 71.2% | 21.3% | ||
| Q3 24 | 69.9% | 20.1% | ||
| Q2 24 | 71.6% | 20.3% | ||
| Q1 24 | 71.9% | 20.8% |
营业利润率CTBBOPCH
| Q4 25 | -183.2% | — | ||
| Q3 25 | 22.3% | 5.9% | ||
| Q2 25 | 33.1% | 5.8% | ||
| Q1 25 | 33.7% | 5.9% | ||
| Q4 24 | 40.7% | 6.9% | ||
| Q3 24 | 38.5% | 6.7% | ||
| Q2 24 | 40.3% | 6.6% | ||
| Q1 24 | 37.6% | 6.0% |
净利率CTBBOPCH
| Q4 25 | -187.5% | — | ||
| Q3 25 | 16.1% | 3.6% | ||
| Q2 25 | 24.3% | 3.6% | ||
| Q1 25 | 24.7% | 3.5% | ||
| Q4 24 | 30.2% | 4.8% | ||
| Q3 24 | 28.2% | 4.2% | ||
| Q2 24 | 28.7% | 4.3% | ||
| Q1 24 | 26.8% | 3.9% |
每股收益（稀释后）CTBBOPCH
| Q4 25 | — | — | ||
| Q3 25 | — | $0.32 | ||
| Q2 25 | — | $0.31 | ||
| Q1 25 | — | $0.28 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | — | $0.31 | ||
| Q2 24 | — | $0.30 | ||
| Q1 24 | — | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $39.0M | $309.8M |
| 总债务越低越好 | $1.7B | $1.2B |
| 股东权益账面价值 | $10.9B | $1.4B |
| 总资产 | $15.8B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.15× | 0.86× |
8季度趋势，按日历期对齐
现金及短期投资CTBBOPCH
| Q4 25 | $39.0M | — | ||
| Q3 25 | $36.0M | $309.8M | ||
| Q2 25 | $25.0M | $198.8M | ||
| Q1 25 | $40.0M | $171.4M | ||
| Q4 24 | $26.0M | $412.6M | ||
| Q3 24 | $22.0M | $483.0M | ||
| Q2 24 | $18.0M | $376.9M | ||
| Q1 24 | $14.0M | $219.5M |
总债务CTBBOPCH
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.7B | $1.1B | ||
| Q1 25 | $1.7B | $1.1B | ||
| Q4 24 | $1.7B | $1.1B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.9B | $1.1B | ||
| Q1 24 | $1.9B | $1.1B |
股东权益CTBBOPCH
| Q4 25 | $10.9B | — | ||
| Q3 25 | $13.0B | $1.4B | ||
| Q2 25 | $12.8B | $1.4B | ||
| Q1 25 | $12.5B | $1.4B | ||
| Q4 24 | $12.2B | $1.4B | ||
| Q3 24 | $11.9B | $1.4B | ||
| Q2 24 | $11.5B | $1.4B | ||
| Q1 24 | $11.1B | $1.4B |
总资产CTBBOPCH
| Q4 25 | $15.8B | — | ||
| Q3 25 | $17.9B | $3.5B | ||
| Q2 25 | $17.8B | $3.4B | ||
| Q1 25 | $17.6B | $3.3B | ||
| Q4 24 | $17.4B | $3.4B | ||
| Q3 24 | $17.0B | $3.4B | ||
| Q2 24 | $16.6B | $3.3B | ||
| Q1 24 | $16.4B | $3.2B |
负债/权益比CTBBOPCH
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.13× | 0.86× | ||
| Q2 25 | 0.13× | 0.82× | ||
| Q1 25 | 0.13× | 0.82× | ||
| Q4 24 | 0.14× | 0.79× | ||
| Q3 24 | 0.14× | 0.78× | ||
| Q2 24 | 0.17× | 0.79× | ||
| Q1 24 | 0.17× | 0.74× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $402.0M | $139.4M |
| 自由现金流经营现金流 - 资本支出 | $160.0M | $130.2M |
| 自由现金流率自由现金流/营收 | 14.5% | 9.1% |
| 资本支出强度资本支出/营收 | 22.0% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 2.69× |
| 过去12个月自由现金流最近4个季度 | $938.0M | $220.7M |
8季度趋势，按日历期对齐
经营现金流CTBBOPCH
| Q4 25 | $402.0M | — | ||
| Q3 25 | $427.0M | $139.4M | ||
| Q2 25 | $480.0M | $90.3M | ||
| Q1 25 | $453.0M | $-7.2M | ||
| Q4 24 | $548.0M | $36.1M | ||
| Q3 24 | $627.0M | $160.4M | ||
| Q2 24 | $548.0M | $195.7M | ||
| Q1 24 | $471.0M | $-68.8M |
自由现金流CTBBOPCH
| Q4 25 | $160.0M | — | ||
| Q3 25 | $252.0M | $130.2M | ||
| Q2 25 | $276.0M | $81.2M | ||
| Q1 25 | $250.0M | $-16.6M | ||
| Q4 24 | $277.0M | $25.8M | ||
| Q3 24 | $396.0M | $150.7M | ||
| Q2 24 | $280.0M | $185.9M | ||
| Q1 24 | $194.0M | $-74.6M |
自由现金流率CTBBOPCH
| Q4 25 | 14.5% | — | ||
| Q3 25 | 23.1% | 9.1% | ||
| Q2 25 | 24.2% | 5.7% | ||
| Q1 25 | 21.7% | -1.2% | ||
| Q4 24 | 21.4% | 2.0% | ||
| Q3 24 | 30.6% | 11.8% | ||
| Q2 24 | 21.3% | 15.1% | ||
| Q1 24 | 14.7% | -6.5% |
资本支出强度CTBBOPCH
| Q4 25 | 22.0% | — | ||
| Q3 25 | 16.0% | 0.6% | ||
| Q2 25 | 17.9% | 0.6% | ||
| Q1 25 | 17.6% | 0.7% | ||
| Q4 24 | 20.9% | 0.8% | ||
| Q3 24 | 17.9% | 0.8% | ||
| Q2 24 | 20.4% | 0.8% | ||
| Q1 24 | 21.0% | 0.5% |
现金转化率CTBBOPCH
| Q4 25 | — | — | ||
| Q3 25 | 2.43× | 2.69× | ||
| Q2 25 | 1.73× | 1.79× | ||
| Q1 25 | 1.60× | -0.15× | ||
| Q4 24 | 1.40× | 0.60× | ||
| Q3 24 | 1.72× | 2.98× | ||
| Q2 24 | 1.45× | 3.69× | ||
| Q1 24 | 1.33× | -1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTBB
| Nonrelated Party | $665.0M | 60% |
| Other | $436.0M | 40% |
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
